



(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 31/12 (2006.01)
C07K 16/28 (2006.01) A01K 67/027 (2006.01)
A61P 37/04 (2006.01) C07K 14/705 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2014/046896

(22) International Filing Date:

16 July 2014 (16.07.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/846,941	16 July 2013 (16.07.2013)	US
61/865,582	13 August 2013 (13.08.2013)	US
61/950,754	10 March 2014 (10.03.2014)	US
61/985,884	29 April 2014 (29.04.2014)	US
61/992,109	12 May 2014 (12.05.2014)	US

(71) Applicant (for all designated States except AL, AT, BA, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR): **GENENTECH, INC.** [US/US]; 1 Dna Way, South San Francisco, CA 94080 (US).

(71) Applicant (for AG, AL, AT, BA, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR only): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors: **GROGAN, Jane**; C/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 (US). **JOHNSTON,**

Robert, J.; C/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 (US). **IRVING, Bryan**; C/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 (US). **HACKNEY, Jason**; C/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 (US). **YU, Xin**; C/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 (US). **EATON, Dan**; C/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 (US). **BOWLES, Kristin**; C/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 (US). **COMPS-AGRAR, Laetitia**; C/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 (US).

(74) Agents: **ZHOU, Jie** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS




FIG. 7C

(57) Abstract: The present disclosure describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— *with sequence listing part of description (Rule 5.2(a))*

Published:

(88) Date of publication of the international search report:

16 April 2015

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*